{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:56:49Z","timestamp":1785178609895,"version":"3.55.0"},"reference-count":18,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The care of the multiple myeloma (MM) patient is complex, with most patients requiring multiple lines of therapy over a span of many years to decades. Since the days when autologous stem cell transplantation became the standard of care for a large subset of patients, it was imperative that community practices and specialized academic centers work together to optimize the initial care of patients. Now, with the unprecedented number of treatment options and the introduction of chimeric antigen receptor T-cell therapies and bispecific T-cell engagers, that collaboration has become even more important and stretches from the upfront treatment to the relapsed and refractory disease setting. I will discuss the unique safety profile and logistical aspects that pose challenges and opportunities for the safe and successful delivery of these therapies. Close interaction, communication, and established partnerships between the primary oncologist, the myeloma specialist, and the transplant or immune effector cell provider will be required to provide the optimal care longitudinally for each patient. This multidisciplinary approach to treating MM can serve as a paradigm for blending community and academic care.<\/jats:p>","DOI":"10.1182\/hematology.2023000431","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:10:09Z","timestamp":1702048209000},"page":"318-323","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Multiple myeloma: a paradigm for blending community and academic care"],"prefix":"10.1182","volume":"2023","author":[{"given":"Jes\u00fas G.","family":"Berdeja","sequence":"first","affiliation":[{"name":"Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"1","key":"2023120815062024100_hem2023000431C1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"2023120815062024100_hem2023000431C2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2023120815062024100_hem2023000431C3","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2023120815062024100_hem2023000431C4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"2023120815062024100_hem2023000431C5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2023120815062024100_hem2023000431C6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2023120815062024100_hem2023000431C7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"2023120815062024100_hem2023000431C8","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"27","key":"2023120815062024100_hem2023000431C9","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"2023120815062024100_hem2023000431C10","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"2023120815062024100_hem2023000431C11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","article-title":"Biomarkers in individualized management of chimeric antigen receptor T cell therapy","volume":"8","author":"Du","year":"2020","journal-title":"Biomark Res"},{"issue":"16_suppl","key":"2023120815062024100_hem2023000431C12","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1200\/JCO.2022.40.16_suppl.8021","article-title":"Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed\/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy","volume":"40","author":"Rytlewski","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023120815062024100_hem2023000431C13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023120815062024100_hem2023000431C14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2023120815062024100_hem2023000431C15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"S1","key":"2023120815062024100_hem2023000431C16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"issue":"5","key":"2023120815062024100_hem2023000431C17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2023120815062024100_hem2023000431C18","first-page":"42","article-title":"Adult survivorship: considerations following CAR T-cell therapy","volume":"23","author":"Buitrago","year":"2019","journal-title":"Clin J Oncol Nurs"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/318\/2175775\/318berdeja.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/318\/2175775\/318berdeja.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:10:20Z","timestamp":1702048220000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/318\/506470\/Multiple-myeloma-a-paradigm-for-blending-community"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000431","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}